Virta Health Reaches Profitability, Now Serving More Than 750 Organizations
Company poised to lead future of metabolic care with expanded clinical evidence, AI capabilities, and new long-term
Press Release Disclaimer: This is a press release distributed through the XPR Media network. It has not been independently verified by our newsroom.
Virta Health, the leader in reversing metabolic disease, today announced its first profitable quarter, reaching a major financial milestone as demand grows for comprehensive metabolic care that delivers better health while lowering costs.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261006807417/en/
Driven by Virta Metabolic Intelligence, members achieved 13% average weight loss at one year without GLP-1 medications.
Virta now serves more than 750 employers, health plans, and government organizations, helping lower their total cost of care while improving cardiometabolic health outcomes like obesity, type 2 diabetes, and cardiovascular disease. Recently named one of the World’s Top HealthTech Companies of 2026 by TIME magazine, this year alone, the company has expanded its clinical evidence across whole-body health, advanced its AI-powered care, reached profitability, attracted new long-term investment, and added deep healthcare operating experience to its Board. Together, the milestones signal a company with growing momentum at a moment when metabolic health has never mattered more.
“Virta has never been stronger, and the opportunity has never been bigger,” said Sami Inkinen, CEO and co-founder of Virta Health. “GLP-1s have changed healthcare for the better, but medication alone won’t solve our metabolic disease crisis. We now have the clinical evidence, technology, financial strength, and experience to deliver something much bigger: comprehensive metabolic care that sustainably reverses disease and improves overall health while bringing costs down. And we’re now ready to scale it to millions more people.”
For more than a decade, Virta has challenged the conventional approach to chronic care management starting with a fundamental idea: metabolic disease is reversible. In 2026 alone, new peer-reviewed research expanded the evidence behind Virta’s nutrition-based approach with evidence extending to chronic inflammation, liver disease, kidney disease, cardiovascular disease, and Stage-IV pancreatic cancer treatment. These published studies build on Virta’s established evidence proving notable outcomes across weight loss, type 2 diabetes reversal, and medication reduction.
Virta is also turning its clinical experience and robust data into increasingly intelligent and individualized care. Metabolic Intelligence, Virta’s AI-powered and clinician-supervised system, connects daily behaviors, biomarkers, medication, and clinical care to deliver personalized guidance that quickly adapts as a member’s health changes. Together with Virta’s comprehensive care model, this technology supports outcomes including 13% average weight loss at one year without GLP-1 medications.1
Entering a new era of growth and innovation, Virta’s first profitable quarter adds another proof point to the company’s endurance: better health can create better value for the organizations paying for care and support a sustainable business.
That combination of clinical, technological, and financial strength is also attracting long-term investment and healthcare leadership. Baillie Gifford, one of the world’s leading investment managers, recently became an equity investor in Virta. The company also welcomed Dr. Rahul Rajkumar, M.D., J.D., CEO of Accompany Health and former COO of Optum Care Solutions, to its Board of Directors.
“We spent our first decade proving what was possible,” said Inkinen. “Now the market is catching up to the opportunity. We have stronger evidence, better technology, more experience, and a stronger business than at any point in our history. We built Virta for this moment, and it’s still day one for us.”
About Virta Health
Virta Health is the leader in reversing metabolic disease. Through their AI-powered platform, Virta combines personalized nutrition, GLP-1 optimization, and clinical support to deliver metabolic care at scale. Virta partners with the nation’s largest employers, payers, and pharmacy benefit managers to help members live longer, healthier lives, while reducing or eliminating the need for medications. Headquartered in Denver, Colorado, Virta is on a mission to reverse metabolic disease in one billion people. For more information, visit www.virtahealth.com.
1McKenzie and Athinarayanan, Diabetes Therapy (2024), never-GLP-1 T2D cohort
View source version on businesswire.com: https://www.businesswire.com/news/home/20261006807417/en/
Media gallery
